Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01350440 | Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia | PHASE2 | COMPLETED | 5 | — | — | Aug 1, 2011 | Jul 1, 2013 | Jul 23, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| IVIG | EXPERIMENTAL | Intravenous Immune Globulin |
| Name | Type | Description |
|---|---|---|
| IVIG | BIOLOGICAL | Intravenous Immune Globulin |
Inclusion Criteria: 1. Outpatients with SCA diagnosed by a movement disorder specialist. 2. Age 10 years to 80 years. 3. Able to ambulate with or without assistance for 30 feet. 4. Women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy tes...